ライフサイエンスコーパス: rheumatic disease

1 recent advances in the field of diabetes and rheumatic disease.

2 Sjogren's syndrome is a common autoimmune rheumatic disease.

3 ity of life in children and adolescents with rheumatic disease.

4 series was efficacious in an animal model of rheumatic disease.

5 s for use in pediatric patients with chronic rheumatic disease.

6 more activity limitations in the setting of rheumatic disease.

7 tion strategies among people with documented rheumatic disease.

8 al adjustment to and coping with a pediatric rheumatic disease.

9 standard and novel agents used in pediatric rheumatic disease.

10 ar disease, and malignancy) in patients with rheumatic disease.

11 in the absence of any objective indicator of rheumatic disease.

12 particularly as they relate to patients with rheumatic disease.

13 specific genetic factors to the spectrum of rheumatic disease.

14 rtant role in the risk of developing chronic rheumatic disease.

15 ician Scale is appropriate for patients with rheumatic disease.

16 ed with adverse birth outcomes in women with rheumatic disease.

17 nce of both inflammatory and noninflammatory rheumatic disease.

18 can result in the development of features of rheumatic disease.

19 bers of repairs in Europe dealt largely with rheumatic disease.

20 ing our understanding of the pathogenesis of rheumatic disease.

21 ted with bicuspid valves and the features of rheumatic disease.

22 e adverse metabolic features associated with rheumatic disease.

23 se phenotype in a mouse model of RRV-induced rheumatic disease.

24 pediatric MAS varies based on the underlying rheumatic disease.

25 e in both adults and children diagnosed with rheumatic disease.

26 estimated the sex-specific lifetime risk of rheumatic disease.

27 MTX initiation among diabetes patients with rheumatic disease.

28 obin (HbA(1c) ) in diabetes patients without rheumatic disease.

29 rtunities to better understand the causes of rheumatic disease.

30 increasingly recognized in association with rheumatic disease.

31 lidates uPA as a novel therapeutic target in rheumatic diseases.

32 ML occurs more commonly in SLE than in other rheumatic diseases.

33 , chronic obstructive pulmonary disease, and rheumatic diseases.

34 with juvenile idiopathic arthritis and other rheumatic diseases.

35 ns of anti-PAD-4 autoantibodies in different rheumatic diseases.

36 , may influence the occurrence of autoimmune rheumatic diseases.

37 its role in the pathogenesis of more common rheumatic diseases.

38 majority of inflammatory and noninflammatory rheumatic diseases.

39 se of their recent success in treating other rheumatic diseases.

40 at may be also useful in patients with other rheumatic diseases.

41 lines on the use of ultrasound modalities in rheumatic diseases.

42 pregnancy and the future risk of autoimmune rheumatic diseases.

43 or for work disability in a diverse array of rheumatic diseases.

44 A helicase A (RHA) in patients with systemic rheumatic diseases.

45 ents have found expanded indication in other rheumatic diseases.

46 est in pharmacoeconomic evaluations in other rheumatic diseases.

47 dated and expanded upon the costs of various rheumatic diseases.

48 rs as they pertain to rehabilitation and the rheumatic diseases.

49 are critical to the pathogenesis of systemic rheumatic diseases.

50 literature concerning work disability in the rheumatic diseases.

51 be increased in association with many of the rheumatic diseases.

52 redispositions, and therapies similar to the rheumatic diseases.

53 been tested as therapeutics for inflammatory rheumatic diseases.

54 a on pregnancy outcomes in women with common rheumatic diseases.

55 psychological well-being among persons with rheumatic diseases.

56 was selected from the National Data Bank for Rheumatic Diseases.

57 ain and pain-related sequelae across several rheumatic diseases.

58 peptides play an important role in juvenile rheumatic diseases.

59 pregnancy-related research in patients with rheumatic diseases.

60 tial lung disease frequently complicates the rheumatic diseases.

61 the validity of the QWB-SA for patients with rheumatic diseases.

62 have been validated in patients with diverse rheumatic diseases.

63 e of this biologic is now expanding to other rheumatic diseases.

64 s and novel biologic agents in children with rheumatic diseases.

65 udies, and may prove useful in other complex rheumatic diseases.

66 therapies used in the treatment of pediatric rheumatic diseases.

67 transplant agents used to treat the various rheumatic diseases.

68 represents a therapeutic option for systemic rheumatic diseases.

69 ct costs, as well as the personal impact, of rheumatic diseases.

70 known targets of autoantibodies in systemic rheumatic diseases.

71 les from patients with systemic immune-based rheumatic diseases.

72 to treat patients with a variety of systemic rheumatic diseases.

73 ave an increased risk of developing systemic rheumatic diseases.

74 chosocial issues for children with pediatric rheumatic diseases.

75 d injury during angiogenesis in inflammatory rheumatic diseases.

76 iters in patients with systemic immune-based rheumatic diseases.

77 mong rheumatologists and among patients with rheumatic diseases.

78 e is known about the quality of care for the rheumatic diseases.

79 be relevant to the pathogenesis of systemic rheumatic diseases.

80 ntal role in the diagnosis and monitoring of rheumatic diseases.

81 o explore as the basis of the HIV-associated rheumatic diseases.

82 ic assays used in the evaluation of systemic rheumatic diseases.

83 volved in vasculitis complicating autoimmune rheumatic diseases.

84 systemic vasculitis may simulate autoimmune rheumatic diseases.

85 to monitor disease activity in patients with rheumatic diseases.

86 on but important manifestation of autoimmune rheumatic diseases.

87 n when testing therapeutic modalities in the rheumatic diseases.

88 cohort of patients with pain due to defined rheumatic diseases.

89 ertinent to the pathogenesis or treatment of rheumatic diseases.

90 h are defective, but correctable, in several rheumatic diseases.

91 udied areas include the muscles, tendons and rheumatic diseases.

92 elopment of inflammatory diseases, including rheumatic diseases.

93 l syndromes that closely mimic other primary rheumatic diseases.

94 nized for noninfectious association with the rheumatic diseases.

95 ty for SLE and 87% specificity against other rheumatic diseases.

96 be difficult to distinguish from idiopathic rheumatic diseases.

97 , including systemic lupus erythematosus and rheumatic diseases.

98 gnify new associations between drugs and the rheumatic diseases.

99 ions of personalized, targeted therapies for rheumatic diseases.

100 ning an effective treatment strategy for the rheumatic diseases.

101 limit the safety of colchicine for treating rheumatic diseases.

102 d localized and generalized bone loss in the rheumatic diseases.

103 ide an effective nonsurgical intervention in rheumatic diseases.

104 emity joint alignment, structure and pain in rheumatic diseases.

105 f foot orthotics and footwear in adults with rheumatic diseases.

106 and interventions that lessen the impact of rheumatic diseases.

107 medical conditions, including the autoimmune rheumatic diseases.

108 of the frequency of PML among patients with rheumatic diseases.

109 for the pathogenesis of chronic inflammatory rheumatic diseases.

110 Among the rheumatic diseases, 43 cases of PML (0.44%) were associa

111 5.5% vs. 0.1%), pancreatic (1.7% vs. 0%) and rheumatic diseases (7.2% vs. 1.2%; all P < 0.01).

112 patients with various systemic immune-based rheumatic diseases (95 with systemic lupus erythematosus

113 with neonatal lupus syndromes do not develop rheumatic diseases, although follow-up is limited to lat

114 btained from our population-based studies of rheumatic diseases among residents of Olmsted County, Mi

115 lales abundance are implicated in arthritis, rheumatic disease and diabetes.

116 acity and physical activity in children with rheumatic disease and examines the role of exercise in m

117 omes compared with those of women with other rheumatic disease and healthy neighborhood controls.

118 However, patients with active underlying rheumatic disease and secondary infection who are being

119 t drugs used in other specialties may induce rheumatic disease and vigilance on making a diagnosis is

120 with aPL detected incidentally, 4 had other rheumatic diseases and 2 had other conditions.

121 th Disabilities Act (ADA) among persons with rheumatic diseases and assessed which factors were assoc

122 y regarding the efficacy of acetaminophen in rheumatic diseases and because apparently safer nonstero

123 ifferences in the occurrence and outcomes of rheumatic diseases and differences in treatment by ethni

124 ecificity in relation to patients with other rheumatic diseases and healthy controls was >90%.

125 SLE patients compared to patients with other rheumatic diseases and healthy subjects.

126 ic abnormality distinguishes SJIA from other rheumatic diseases and is caused by both genetic and acq

127 a potential means for the differentiation of rheumatic diseases and may provide insight into disease

128 Patients with inflammatory rheumatic diseases and periodontitis share common pathog

129 rophylaxis in immunosuppressed patients with rheumatic diseases and screening that clinicians should

130 th content that was relevant to rheumatology/rheumatic diseases and that primarily focused on ethics.

131 rheumatologists in caring for children with rheumatic diseases and the quality of the care that they

132 Children and adolescents with rheumatic diseases and their families face a multitude o

133 isks of malignancy associated with pediatric rheumatic diseases and their treatments are needed.

134 s have been developed and validated for many rheumatic diseases and used in clinical trials.

135 logic lesion, the activity of the underlying rheumatic disease, and associated pulmonary hypertension

136 d (210 SLE patients, 178 patients with other rheumatic diseases, and 205 healthy subjects).

137 Job loss is a major consequence of rheumatic diseases, and clinicians may refer patients to

138 nts with established RA, patients with other rheumatic diseases, and healthy adults were assayed for

139 y was confined to hospitalized patients with rheumatic diseases, and it was also limited by the lack

140 are key pathogenic derangements in systemic rheumatic diseases, and these insights are leading to ch

141 ch as cyclosporine and FK506 in a variety of rheumatic diseases; and 3) toxicity.

142 e use of immunomodulatory drugs, many of the rheumatic diseases appear to pose an increased risk for

143 ic bacteriuria (AB) in women with autoimmune rheumatic disease (ARD) are scarce.

144 Ocular manifestations of rheumatic disease are common and varied.

145 Features that can have similarities to many rheumatic diseases are being increasingly reported.

146 Autoantibodies in the systemic rheumatic diseases are clinically useful biomarkers of t

147 ibroblasts in systemic sclerosis and related rheumatic diseases are discussed.

148 As most of the rheumatic diseases are multisystem, it is worthwhile exa

149 This morbidity is undetermined in pediatric rheumatic disease as osteoporosis has not been well-defi

150 d between healthy children and children with rheumatic diseases as a group.

151 largely from the Royal National Hospital for Rheumatic Diseases AS database.

152 Scleroderma is a chronic autoimmune rheumatic disease associated with widespread tissue fibr

153 pneumonia accounts for a large proportion of rheumatic disease-associated interstitial lung diseases.

154 Macrophage activation syndrome is the rheumatic disease-associated member of a group of hyperi

155 le, other interventions are needed to reduce rheumatic disease-associated work disability.

156 the principles behind RNA sequestration by a rheumatic disease autoantigen, whereby the UUU(OH) 3' en

157 Ultrasound cannot identify specific rheumatic diseases, but it does allow for an evaluation

158 genitor/stem cells (MPCs) and their roles in rheumatic diseases, but little is known about the phenot

159 portant mediator of cartilage destruction in rheumatic diseases, but our understanding of the upstrea

160 ologists document and improve the quality of rheumatic disease care.

161 and improving access to and coordination of rheumatic disease care.

162 siological mechanisms of musculoskeletal and rheumatic disease caused by SINV are inadequately unders

163 c lupus erythematosus (SLE), an inflammatory rheumatic disease characterized by autoantibody producti

164 were identified from patients attending the Rheumatic Diseases Clinic, Hospital de Santo Espirito, i

165 f 113 individuals (73% women) with diagnosed rheumatic disease completed a mailed questionnaire.

166 ystem dysfunction is common in children with rheumatic diseases complicated by MAS, and more organ sy

167 specific genetic mechanisms involved in the rheumatic diseases continues to present considerable cha

168 48 SLE patients, 48 normal controls, and 22 rheumatic disease controls, and total RNA was extracted

169 Studies of children with chronic rheumatic disease demonstrate decreased bone mineral den

170 fficacy, and the safety of plasmapheresis in rheumatic diseases demonstrates that the answer depends

171 and safety of intravenous immunoglobulins in rheumatic diseases demonstrates that the answer depends

172 limitations in children and adolescents with rheumatic disease despite advances in the pharmacologica

173 ealth indicator that shows differences among rheumatic disease diagnoses.

174 ons and 11.9% of return visits was neither a rheumatic disease diagnosis nor a musculoskeletal compla

175 ured medical record abstraction, we examined rheumatic disease diagnosis, cumulative steroid use, dur

176 men will develop an inflammatory autoimmune rheumatic disease during their lifetime.

177 s for specific immunization of patients with rheumatic diseases, especially those treated with immuno

178 Although many persons with rheumatic diseases experience community barriers or need

179 ta concerning vaccination among persons with rheumatic diseases, focusing on the effects of immune-mo

180 ts promise to shape the care of RA and other rheumatic diseases for many years to come.

181 Children with rheumatic diseases frequently require therapy with disea

182 underlying the pathogenenesis of autoimmune rheumatic diseases has led to targeted biological treatm

183 cial health care needs, including youth with rheumatic diseases, has markedly improved.

184 S: New genetic associations in patients with rheumatic disease have been reported for disease modifyi

185 Children with chronic rheumatic disease have decreased bone mass.

186 Several juvenile rheumatic diseases have been linked to certain immunomod

187 The options for treating rheumatic diseases have improved, but many patients are

188 tological malignancies, Crohn's disease, and rheumatic diseases--have been associated with PML.

189 Both atherosclerosis and rheumatic diseases, however, have a complicated cause, a

190 he highest case-specific mortality among the rheumatic diseases; however, advances in understanding o

191 ng of the immunopathology of childhood-onset rheumatic diseases; however, considerable impediments mu

192 literature related to the risk of autoimmune rheumatic disease in association with pregnancy history.

193 Although mortality from rheumatic disease in children is rare, the most severe d

194 squito-borne Alphavirus, causes debilitating rheumatic disease in humans that can last for weeks to m

195 Gout is a common rheumatic disease in humans which is characterized by el

196 ging typical for the most commonly diagnosed rheumatic diseases in children, such as juvenile idiopat

197 n the prevalence or characteristics of other rheumatic diseases in the US Hispanic population.

198 Spondyloarthropathies belong to a group of rheumatic diseases, in which inflammatory changes affect

199 ted by 688 consecutive patients with various rheumatic diseases, including 162 with rheumatoid arthri

200 dal anti-inflammatory drugs in patients with rheumatic diseases, including children.

201 c lesions cause interstitial lung disease in rheumatic diseases, including nonspecific interstitial p

202 Finally, rheumatic diseases, including rheumatoid arthritis and s

203 RA, as well as other inflammatory autoimmune rheumatic diseases, including systemic lupus erythematos

204 The diagnosis of a rheumatic disease is no longer an absolute contraindicat

205 of interstitial lung disease associated with rheumatic disease is similar to that associated with the

206 eally better understand the genetic basis of rheumatic diseases is advancing at a rapid pace.

207 Current therapy for juvenile rheumatic diseases is based on general immune suppressio

208 nce of cultural aspects of rehabilitation in rheumatic diseases is being increasingly recognized and

209 Differential diagnosis of rheumatic diseases is performed on the basis of localiza

210 magnitude of this advance in the therapy of rheumatic diseases is yet to be accurately determined, b

211 Thus, as with other multisystem rheumatic diseases, it is difficult to quantify the leve

212 aphies that met inclusion criteria, selected rheumatic disease journals, and abstracts from scientifi

213 caring for patients, few reports within the rheumatic disease literature have focused on ethical iss

214 basis of the disease has lagged behind other rheumatic diseases mainly because of the difficulty in d

215 ntigen are associated with distinct clinical rheumatic disease manifestations.

216 tic elements regulating human autoimmune and rheumatic diseases may be much larger and more varied th

217 Autoimmune rheumatic diseases may present as systemic vasculitis, a

218 Interstitial lung disease is common in the rheumatic diseases, may be caused by a variety of lesion

219 trasound is used in the initial diagnosis of rheumatic diseases, monitoring of the effectiveness of t

220 They also had thyroid or rheumatic diseases more commonly (42% vs. 13%, P = .006)

221 inherited or acquired, children with severe rheumatic diseases, most notably systemic juvenile idiop

222 ith PBC (n = 30), other autoimmune liver and rheumatic diseases (n = 20), and healthy individuals (n

223 Participants in the National Data Bank for Rheumatic Diseases (NDB) longitudinal study of long-term

224 were enrolled in the National Data Bank for Rheumatic Diseases (NDB).

225 nile idiopathic arthritis (JIA) is a chronic rheumatic disease of childhood.

226 opens the possibility of clinical testing in rheumatic diseases of childhood.

227 potential to provide novel insights into the rheumatic diseases of childhood.

228 igms with which to understand this and other rheumatic diseases of childhood.

229 e diagnostics and treatment of patients with rheumatic diseases of the musculoskeletal system, includ

230 present in sera from patients with systemic rheumatic diseases, often in combination with4=1998 M au

231 in SLE patients than in patients with other rheumatic diseases or healthy controls (P < 0.0001).

232 its to rheumatologists involve patients with rheumatic diseases or musculoskeletal complaints, and fe

233 alized or consultative care to patients with rheumatic diseases or musculoskeletal complaints, and fe

234 n = 2,484) on mailing lists of participating rheumatic disease organizations.

235 e studied the HAQ-II in 14,038 patients with rheumatic disease over a 2-year period to determine its

236 e risk of developing inflammatory autoimmune rheumatic disease over a lifetime.

237 with scleroderma, and 261 with various other rheumatic diseases, over 2 years at a weekly academic rh

238 Opioid treatment of chronic rheumatic disease pain is controversial because of conce

239 ding opioids from patients with well-defined rheumatic disease pain.

240 tcomes of pregnancy after the onset of their rheumatic disease, particularly premature births (also s

241 ugs (NSAIDs) are being produced, we surveyed rheumatic disease patients about their preferences for t

242 As prognosis for rheumatic disease patients continues to improve, the imp

243 inhibitors (statins) to improve outcomes in rheumatic disease patients correlates with the activitie

244 linical disease manifestations, sera from 27 rheumatic disease patients with U1-70-kd antibodies were

245 red with acetaminophen among the 3 groups of rheumatic disease patients.

246 As a result of the chronic nature of rheumatic diseases, pharmacoeconomic evaluations must be

247 Pediatric rheumatic diseases present psychosocial challenges for p

248 tology journals, we identified RCTs of adult rheumatic diseases published in English in 1987-1988 or

249 Patients with rheumatic diseases receiving certain therapeutic agents

250 rome (SS), the second most common autoimmune rheumatic disease, refers to keratoconjunctivitis sicca

251 SLE, but not in patients with other systemic rheumatic diseases, regardless of disease activity, trea

252 isks for rheumatoid arthritis (RA) and other rheumatic diseases remains poor, despite advances in kno

253 With the growth in patient registries in rheumatic disease research, it is important to validate

254 A total of 242 patients with rheumatic diseases residing in Massachusetts were recrui

255 nsive cells in both the bona fide autoimmune rheumatic diseases rheumatoid arthritis and systemic lup

256 with AS from the Royal National Hospital for Rheumatic Diseases (RNHRD) database and BASMI data on 39

257 in unaffected cases, independent of maternal rheumatic disease, season at highest risk of cardiac NL

258 sible involvement of HRV-5 in autoimmune and rheumatic disease should be investigated further.

259 Children with chronic rheumatic disease should have bone mass monitored by dua

260 mic factors at the level of individuals with rheumatic diseases; sometimes, our scope of inquiry expa

261 n the medical interaction with patients with rheumatic disease specifically, there is a large body of

262 protein-containing ICs from other autoimmune rheumatic diseases, stimulates plasmacytoid DCs (PDCs) t

263 omplaints, which can present as a definitive rheumatic disease such as calcium pyrophosphate dihydrat

264 afety in rheumatoid arthritis (RA) and other rheumatic diseases such as juvenile idiopathic arthritis

265 of sarcoidosis coexisting with or mimicking rheumatic diseases such as systemic lupus erythematosus,

266 A and TST in a large cohort of patients with rheumatic diseases suggest that the IGRA provides greate

267 Patients with the autoimmune rheumatic disease systemic lupus erythematosus (SLE) hav

268 Similar to the majority of autoimmune rheumatic diseases, systemic sclerosis is characterized

269 te antigen B27 is highly associated with the rheumatic diseases termed spondyloarthropathies, but the

270 irus (CHIKV) infection causes a debilitating rheumatic disease that can persist for months to years,

271 eins, which are autoantigens associated with rheumatic disease that function in RNA biogenesis and qu

272 so called scleroderma, is an immune-mediated rheumatic disease that is characterised by fibrosis of t

273 The spondyloarthropathies are a group of rheumatic diseases that are associated with inflammation

274 related and overlapping chronic inflammatory rheumatic diseases that primarily include ankylosing spo

275 described as an autoantigen in patients with rheumatic disease, the La protein binds to newly synthes

276 Studies of the costs associated with rheumatic diseases, the referral of patients to rheumato

277 As with many rheumatic diseases, there is growing interest in using g

278 er diseases can be extended to patients with rheumatic disease, this review also covers the most sali

279 mediated diseases (diabetes mellitus type 1, rheumatic disease, thyroid disease, vitiligo, alopecia a

280 ppressive agents often require patients with rheumatic diseases to be monitored or managed in the ped

281 GSTs should be considered for rheumatic disease treatment trials.

282 In today's modern day treatment of rheumatic diseases, ultrasonography and magnetic resonan

283 ability to identify and treat children with rheumatic diseases, undermine resident interest in this

284 all lifetime risk of inflammatory autoimmune rheumatic disease was 8.4% for women and 5.1% for men.

285 e second most common inflammatory autoimmune rheumatic disease was PMR, with a lifetime risk of 2.4%

286 ide profile, or sugar print, for each of the rheumatic diseases was found.

287 ra obtained from patients with SLE and other rheumatic diseases was measured by an enzyme-linked immu

288 hat the overall mortality rate for pediatric rheumatic diseases was not increased.

289 using on cancer, cardiovascular disease, and rheumatic diseases, we review longitudinal investigation

290 t four groups of drugs to potentially induce rheumatic diseases were anti-tumour necrosis factor (TNF

291 ystemic lupus erythematosus (SLE), and other rheumatic diseases were identified by diagnostic codes f

292 5 years of age in the National Data Bank for Rheumatic Diseases were used, along with US population d

293 onal rehabilitation provided to persons with rheumatic diseases while they are still employed, but at

294 in the treatment of patients with autoimmune rheumatic diseases who have failed conventional therapy.

295 nt IFN pathways active in tissues of complex rheumatic diseases will be critical to classify disease,

296 Trials treating human rheumatic diseases with biologic agents and drugs that s

297 reviews ongoing research on the treatment of rheumatic diseases with new and existing biologic agents

298 nt cultural aspects of rehabilitation in the rheumatic diseases with several societal as well as indi

299 es in the biological treatment of autoimmune rheumatic diseases, with a particular focus on systemic

300 ntibody rituximab is a novel therapy for the rheumatic diseases, with an increasing body of evidence